Cinepazide maleateAlternative Names: Anjieli; Kelinao
Latest Information Update: 25 Sep 2013
At a glance
- Originator Sihuan Pharmaceutical Holdings Group
- Class Antiparkinsonians; Neuroprotectants; Peripheral vasodilators
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Ischaemia
Most Recent Events
- 31 Oct 2012 Sihuan Pharmaceutical initiates a post-marketing surveillance trial in Chinese patients (NCT01946919; PACER)